A significant new study from Stanford University suggests that women who used estrogen only menopausal hormone therapy may face a substantially lower risk of developing Alzheimer’s disease and dementia. By analyzing post mortem data from more than 21,000 participants, researchers discovered that those using the specific hormone treatment had a 35 percent lower chance of showing Alzheimer’s related brain pathology and a 39 percent lower likelihood of dementia over their lifetime compared to those who did not use the therapy.
The research focused specifically on the physical markers of the disease, examining brains for the presence of amyloid plaques and neurofibrillary tangles, which are the primary hallmarks of Alzheimer’s. Beyond the biological evidence, the study found that some living participants who utilized estrogen only therapy performed better on memory tests and maintained a higher level of independent functioning. Experts believe this is because estrogen helps protect neurons, reduces inflammation in the brain, and prevents the buildup of toxic proteins associated with cognitive decline.
Interestingly, the researchers noted that since many women in the study began their treatment later in life, the observed benefits might actually be an underestimate. Current theories suggest that hormone therapy may provide even stronger protection if started during or immediately following menopause. These findings challenge previous studies that suggested a link between hormone therapy and an increased risk of dementia, providing a fresh perspective on why women make up roughly two thirds of all Alzheimer’s diagnoses.
Despite these promising results, scientists urge caution against making immediate medical changes based on this data alone. Because the study was observational rather than a controlled trial, it shows a strong correlation but cannot definitively prove that hormone therapy caused the reduction in risk. Factors like overall baseline health or regular access to healthcare could have played a role in the outcomes. Lead authors emphasize that while these signals are encouraging, larger prospective trials are necessary before changing clinical guidelines regarding menopausal treatments for brain health.